The present disclosure features a cross-linked chemical entity (e.g., a compound or a pharmaceutically acceptable salt and / or
hydrate and / or
prodrug of a compound) in the
cornea in response to
exposure to
electromagnetic radiation. The disclosure also features compositions comprising the chemical entities as well as other methods of use and preparation thereof. The chemical entities may be used, for example, to treat a subject (e.g., a person) having a
disease, disorder or condition in which
abnormal shapes of the
cornea (e.g., corneal
thinning, e.g., bilateral corneal
thinning, e.g., bilateral
thinning of the central, paracentral or
peripheral cornea; or corneal steepage (e.g., protuberance), resulting in a
pathology and / or symptom and / or progression of a
disease, disorder or condition. Non-limiting examples of such diseases, disorders or conditions include: (i) corneal dilation
disease; (ii) a visual condition; (iii) is a disease, disorder or condition after or coexisting with any of the above-described or any of the disease, disorder or condition described herein. More specific non-limiting examples of such diseases, disorders or conditions include cornea conus, corneal globe, transparent edge degeneration, corneal dilation (e.g., post-operative dilation, e.g.,
LASIK post-operative dilation), Terrien edge degeneration, myopia, hyperopia,
astigmatism, irregular
astigmatism, and
presbyopia.